<DOC>
	<DOCNO>NCT00823238</DOCNO>
	<brief_summary>This prospective , randomized clinical trial compare effect 2 mode antibiotic treatment BALF inflammation young , P. aeruginosa-positive CF patient .</brief_summary>
	<brief_title>Comparison Antibiotics Pseudomonas Early CF</brief_title>
	<detailed_description>Cystic fibrosis ( CF ) genetic disorder typically fatal early adulthood , due progressive bronchiectasis respiratory failure . Chronic lung infection Pseudomonas aeruginosa begin early life clearly associate decline ( especially mucoid phenotype ) , make infection major target therapy . The inflammatory response infection may also dysregulated CF , suppression airway inflammation second major goal therapy . However , `` best practice '' treatment Pseudomonas infection early CF define ( several recently publish commentary available upon request ) critical issue currently clinical management CF . Inhaled tobramycin alone report effective short-term eradication P. aeruginosa bronchoalveolar lavage fluid ( BALF ) child cystic fibrosis ( CF ) age 3 mo-6 yr , inflammation unaffected treatment , recurrence infection occur fairly quickly mucoid strain . The ideal treatment would result long-term reduction bacterial quantity inflammation . Some bacteria CF airway may inaccessible inhaled antibiotic , `` hidden '' BALF , location inspissate secretion , P. aeruginosa may effectively eradicate paranasal sinus . Thus , reasonable hypothesize treatment parenteral antibiotic provide good overall eradication organism consequently reduce stimulus ongoing recurrent inflammation airway . We therefore propose prospective , randomized clinical trial compare effect 2 mode antibiotic treatment BALF inflammation young , P. aeruginosa-positive CF patient .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<criteria>1 . Positive respiratory culture ( sputum , BALF , deep pharyngeal culture ) past 3 month P. aeruginosa . Those culture positive P. aeruginosa additional bacteria ( S. aureus , H. influenzae ) would also eligible ( see microbiologic exclusion ) . Children either first isolate chronic/repeated P. aeruginosa infection eligible . 2 . Clinically stable define : 1 . No systemic antiP . aeruginosa antibiotic past 2 mo , TOBI past 1 month ; 2 . No pulmonary exacerbation past 1 mo ( definition furnish request ) ; 3 . FEV1 â‰¥ 70 % predict ( best baseline past 6 month study entry ) old enough reliably test spirometric lung function . 1 . Recent ( within past 2 mo ) use systemic antiPseudomonas antibiotic , exception chronic ( three time week ) azithromycin ; 2 . Recent ( within past 2 wk ) use systemic antiinflammatory agent ; 3 . Mycobacterial pathogen AFB smear initial bronchoscopy ; 4 . Multipledrug resistant ( MDR ) P. aeruginosa , oxacillinresistant S. aureus ( ORSA ) respiratory culture past 3 month . If either MDRP . aeruginosa , ORSA isolate initial bronchoscopy , subject exclude result discuss primary caregiver . 5 . Viral pathogen occasionally isolated BALF may take 23 week . Thus , subject result initial bronchoscopy likely complete treatment protocol , would undergo bronchoscopy # 2 . 6 . History reaction problem anesthesia sedation . 7 . History reaction problem aminoglycosides ( medicine like tobramycin gentamicin ) . 8 . History hemoptysis ( cough blood ) within 30 day prior entry . 9 . History anemia thrombocytopenia . 10 . Administration investigational drug within 30 day prior entry . 11 . History abnormal kidney function ( great 1.5 time upper limit normal serum creatinine age ) . 12 . History document chronic hearing loss . 13. child age 3 month , prematurity define gestational age &lt; 36 week .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>